Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05358938 · ClinicalTrials.gov registry record · Early Phase 1
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
A Early Phase 1 study of Cutaneous Melanoma and Merkel Cell Carcinoma, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Active
- Registry status
- Early Phase 1
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT05358938 is a Early Phase 1 study of Cutaneous Melanoma and Merkel Cell Carcinoma that is active but no longer recruiting, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 22 participants, below the 366-participant average among 30 other Cutaneous Melanoma trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05358938, a Early Phase 1 study of Cutaneous Melanoma and Merkel Cell Carcinoma, is active but no longer recruiting, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
30 minutes of moderate exercise on an arm ergometer, a cycle ergometer, or a treadmill prior to each administration of standard of care checkpoint blockade immunotherapy across all cycles
Conditions Studied
Interventions
- OTHER Exercise
- DRUG Checkpoint Blockade, Immune
Study Locations (1)
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2022-06-21 |
| Est. Completion | 2026-08 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05358938
The ClinicalTrials.gov registry entry for NCT05358938 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 366-participant average among 30 other Cutaneous Melanoma trials with a reported enrollment target (94% lower). The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Cutaneous Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Exercise is the first listed.
NCT05358938 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05358938 about?
NCT05358938 is a clinical study titled "Exercise to Boost Response to Checkpoint Blockade Immunotherapy". 30 minutes of moderate exercise on an arm ergometer, a cycle ergometer, or a treadmill prior to each administration of standard of care checkpoint blockade immunotherapy across all cycles
What is the current status of trial NCT05358938?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 22 participants. The study started on 2022-06-21. Estimated completion is 2026-08.
What conditions does trial NCT05358938 study?
This clinical trial studies the following conditions: Cutaneous Melanoma, Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma.
What interventions are being tested in trial NCT05358938?
The interventions under investigation include: Exercise (OTHER), Checkpoint Blockade, Immune (DRUG).
Who is sponsoring clinical trial NCT05358938?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05358938 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cutaneous Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma
RECRUITING
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
RECRUITING · Phase 2
-
ACTengine® IMA203 Combined With mRNA-4203
RECRUITING · Phase 1
-
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.